These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. Elborn JS; Ramsey BW; Boyle MP; Konstan MW; Huang X; Marigowda G; Waltz D; Wainwright CE; Lancet Respir Med; 2016 Aug; 4(8):617-626. PubMed ID: 27298017 [TBL] [Abstract][Full Text] [Related]
7. Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV McColley SA; Konstan MW; Ramsey BW; Stuart Elborn J; Boyle MP; Wainwright CE; Waltz D; Vera-Llonch M; Marigowda G; Jiang JG; Rubin JL J Cyst Fibros; 2019 Jan; 18(1):94-101. PubMed ID: 30146268 [TBL] [Abstract][Full Text] [Related]
8. Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosis. Wagener JS; Williams MJ; Millar SJ; Morgan WJ; Pasta DJ; Konstan MW J Cyst Fibros; 2018 Jul; 17(4):496-502. PubMed ID: 29685810 [TBL] [Abstract][Full Text] [Related]
9. Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis. McElvaney OJ; Heltshe SL; Odem-Davis K; West NE; Sanders DB; Fogarty B; VanDevanter DR; Flume PA; Goss CH Ann Am Thorac Soc; 2024 May; 21(5):716-726. PubMed ID: 38096105 [No Abstract] [Full Text] [Related]
10. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis. Heltshe SL; Goss CH; Thompson V; Sagel SD; Sanders DB; Marshall BC; Flume PA Thorax; 2016 Mar; 71(3):223-9. PubMed ID: 25911223 [TBL] [Abstract][Full Text] [Related]
12. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site. Schechter MS; Regelmann WE; Sawicki GS; Rasouliyan L; VanDevanter DR; Rosenfeld M; Pasta D; Morgan W; Konstan MW Pediatr Pulmonol; 2015 May; 50(5):431-40. PubMed ID: 25530325 [TBL] [Abstract][Full Text] [Related]
13. Correspondence between lung function and symptom measures from the Cystic Fibrosis Respiratory Symptom Diary-Chronic Respiratory Infection Symptom Score (CFRSD-CRISS). Gold LS; Patrick DL; Hansen RN; Goss CH; Kessler L J Cyst Fibros; 2019 Nov; 18(6):886-893. PubMed ID: 31126901 [TBL] [Abstract][Full Text] [Related]
14. Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes. Sanders DB; Zhao Q; Li Z; Farrell PM Pediatr Pulmonol; 2017 Oct; 52(10):1268-1275. PubMed ID: 28881091 [TBL] [Abstract][Full Text] [Related]
15. Quantifying variation in home spirometry in people with cystic fibrosis during baseline health, and associations with clinical outcomes. Thornton CS; Magaret AS; Carmody LA; Kalikin LM; Simon RH; LiPuma JJ; Caverly LJ J Cyst Fibros; 2024 Mar; 23(2):321-328. PubMed ID: 37244842 [TBL] [Abstract][Full Text] [Related]
16. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor. Flume PA; Wainwright CE; Elizabeth Tullis D; Rodriguez S; Niknian M; Higgins M; Davies JC; Wagener JS J Cyst Fibros; 2018 Jan; 17(1):83-88. PubMed ID: 28651844 [TBL] [Abstract][Full Text] [Related]